Literature DB >> 26215544

Rural vs. urban disparities in association with lower urinary tract symptoms and benign prostatic hyperplasia in ageing men, NHANES 2001-2008.

K B Egan1, M Suh1, R C Rosen1, A L Burnett2, X Ni3, D G Wong4, K T McVary5.   

Abstract

OBJECTIVE: The objective of this study was to investigate rural/urban and socio-demographic disparities in lower urinary tract symptoms and benign prostatic hyperplasia (LUTS/BPH) in a nationally representative population of men.
METHODS: Data on men age ≥40 years (N = 4,492) in the 2001-2008 National Health and Nutrition Examination Surveys were analysed. Self-report of physician-diagnosed enlarged prostate and/or BPH medication use defined recognised LUTS/BPH. Urinary symptoms without BPH diagnosis/medications defined unrecognised LUTS/BPH. Rural-Urban Commuting Area Codes assessed urbanisation. Unadjusted and multivariable associations (odds ratios (OR)) between LUTS/BPH and covariates were calculated using logistic regression.
RESULTS: Recognised and unrecognised LUTS/BPH weighted-prevalence estimates were 16.5% and 9.6%. There were no significant associations between LUTS/BPH and rural/urban status. Significant predisposing factors for increased adjusted odds of recognised and unrecognised LUTS/BPH included age, hypertension (OR=1.4;1.4), analgesic use (OR=1.4;1.4) and PSA level >4 ng/mL (OR=2.3;1.9) when adjusted for rural/urban status, race, education, income, alcohol, health insurance, health care and proton pump inhibitor (PPI) use (all p ≤ 0.1). Restricting to urban men only (N = 3,371), healthcare use (≥4visits/year) and PPI's increased adjusted odds of recognised LUTS/BPH (OR=2.0;1.6); no health insurance and <high school education decreased odds (OR=0.5;0.6) after adjusting for variables listed above, antidepressant and calcium channel blocker use (p ≤ 0.1). Also among urban men, adjusted odds of unrecognised LUTS/BPH increased for blacks (OR=1.9), Hispanic/Other (OR=1.9) and income<$34,999 (OR=1.6). Among rural men only (N = 1,121), adjusted odds of recognised and unrecognised LUTS/BPH increased for age, hypertension (OR=1.9;1.7) and analgesic use (OR=2.0;1.5) when adjusting for race, CRP, antidepressant and dyslipidaemic use (p ≤ 0.1).
CONCLUSION: Rural/urban status was not associated with significantly increased adjusted odds of either recognised or unrecognised LUTS/BPH.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2015        PMID: 26215544     DOI: 10.1111/ijcp.12709

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  5 in total

1.  The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis.

Authors:  Shaun Wen Huey Lee; Esther Mei Ching Chan; Yin Key Lai
Journal:  Sci Rep       Date:  2017-08-11       Impact factor: 4.379

2.  Prevalence and bother of lower urinary tract symptoms and overactive bladder in Poland, an Eastern European Study.

Authors:  Mikolaj Przydacz; Tomasz Golabek; Przemyslaw Dudek; Marek Lipinski; Piotr Chlosta
Journal:  Sci Rep       Date:  2020-11-13       Impact factor: 4.379

3.  Analysis of the relationship between asthma and benign prostatic hyperplasia: A STROBE-compliant study.

Authors:  Jee Hye Wee; Woo Jin Bang; Min Woo Park; Soo-Hwan Byun; Hyo Geun Choi
Journal:  Medicine (Baltimore)       Date:  2021-03-19       Impact factor: 1.817

4.  A community-based study on lower urinary tract symptoms in Malaysian males aged 40 years and above.

Authors:  Mohamad Fuad Mohamad Anuar; Muhammad Solihin Rezali; Mohamed Ashraf Mohamed Daud; Shaiful Bahari Ismail
Journal:  Sci Rep       Date:  2022-02-11       Impact factor: 4.379

Review 5.  Role of α1-blockers in the current management of hypertension.

Authors:  Hua Li; Ting-Yan Xu; Yan Li; Yook-Chin Chia; Peera Buranakitjaroen; Hao-Min Cheng; Minh Van Huynh; Guru Prasad Sogunuru; Jam Chin Tay; Tzung-Dau Wang; Kazuomi Kario; Ji-Guang Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-09       Impact factor: 2.885

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.